Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr382 Inhibitors

Olr382 inhibitors represent a unique and evolving class of chemical compounds that are characterized by their specific ability to modulate the activity of the olfactory receptor Olr382, a member of the G-protein coupled receptor (GPCR) superfamily. Olr382, like other olfactory receptors, plays a critical role in detecting and responding to odorant molecules. The inhibition of this receptor can be studied in the context of its molecular interaction with various ligands, allowing researchers to explore the nuanced mechanisms by which olfactory signals are modulated at the cellular level. The inhibitors are often designed or identified through high-throughput screening, followed by structural optimization to enhance selectivity and affinity for Olr382. These compounds are crucial in unraveling the molecular details of odorant-receptor binding and signal transduction pathways, providing insight into the broader family of olfactory receptors and their roles in sensory biology.

The chemical structure of Olr382 inhibitors is typically optimized for high receptor binding specificity and minimal off-target effects, which is critical for studying the isolated functions of Olr382. Structural features often include specific aromatic or heteroaromatic moieties that interact with key amino acid residues within the receptor's binding pocket. Detailed studies, including crystallography or molecular dynamics simulations, are frequently employed to map out these interactions at an atomic level, offering a clear picture of how these inhibitors achieve their selective binding. Additionally, the pharmacokinetic properties of these inhibitors, such as their metabolic stability, lipophilicity, and membrane permeability, are meticulously characterized to ensure they effectively reach their target within cellular environments. The study of Olr382 inhibitors, therefore, not only contributes to our understanding of olfactory receptor functionality but also provides a framework for exploring the broader roles of GPCRs in various biological processes.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted receptor tyrosine kinase (RTK) inhibitor, potentially disrupts VEGF and PDGF signaling pathways.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor, potentially modulates cytokine and growth factor signaling crucial in hematologic malignancies.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, potentially disrupts the MAPK/ERK pathway, crucial in melanoma and other cancers.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, potentially affects NF-κB signaling and cell cycle regulation.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Bruton's tyrosine kinase (BTK) inhibitor, potentially alters B-cell receptor signaling in lymphomas.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

BRAF inhibitor, potentially targets the MAPK/ERK pathway in melanoma with BRAF V600 mutations.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

ALK inhibitor, potentially targets ALK-positive non-small cell lung cancer by disrupting ALK-mediated signaling.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

MEK1/2 inhibitor, potentially affects the RAS/RAF/MEK/ERK pathway in various cancers.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, potentially regulates cell cycle progression in breast cancer.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Multi-kinase inhibitor, potentially affects MET, VEGFR, and AXL signaling in medullary thyroid cancer.